Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.32 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | NPY2R | P49146 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3606470 | 1.00 | KDM4E (0.33) | KDM4EALDH1A1AOC3SCN9ANPY5R | |
| SCHEMBL30724468 | 0.79 | MEN1 (0.38) | ALDH1A1LMNA | |
| SCHEMBL3807540 | 0.77 | ADRB2 (0.38) | AOC3LMNACYP2C9CYP2C19 | |
| Erythro Anethole Glycol SCHEMBL3234807 | 0.75 | AOC3 (0.53) | ALDH1A1AOC3CYP2C19 | |
| SCHEMBL15974976 | 0.75 | ESR2 (0.44) | KDM4EALDH1A1LMNAHIF1A | |
| SCHEMBL112627 | 0.74 | AKR1C3 (0.50) | LMNACYP2C9CYP2C19 | |
| SCHEMBL2103658 | 0.73 | NPY5R (0.32) | KDM4EALDH1A1NPY5R | |
| SCHEMBL13043497 | 0.73 | ACHE (0.44) | ALDH1A1LMNACYP2C9 | |
| SCHEMBL3085551 | 0.72 | TRPA1 (0.36) | ALDH1A1 | |
| SCHEMBL2099024 | 0.72 | ESR1 (0.33) | KDM4EALDH1A1ADRA2ALMNAHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168156-A1 | Novel Benzoxathiine Derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-07-01 | — | — | US | disclosed |
| EP-1944301-A1 | NOVEL BENZOXATHIIN DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-07-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168156-A1 | Novel Benzoxathiine Derivative | XDH, GPR119, BRIX1 | KDM4E 1777/4885ALDH1A1 1579/4885AOC3 781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.